健康之路
健康之路
건강지로
HEALTH
2014年
12期
8-8
,共1页
心力衰竭%和肽素%N端脑钠肽前体%贝那普利%美托洛尔缓释片
心力衰竭%和肽素%N耑腦鈉肽前體%貝那普利%美託洛爾緩釋片
심력쇠갈%화태소%N단뇌납태전체%패나보리%미탁락이완석편
Heart failure%Copeptin%N terminal brain natriuretic peptide%Benazepril%Metoprolol succinate sustained-release tablet
目的：：观察贝那普利联合美托洛尔缓释片对慢性心力衰竭患者血清和肽素及 N端脑钠肽前体(NT－proBNP)的影响，探讨贝那普利联合美托洛尔缓释片抑制心室重构的作用机制。方法：慢性心力衰竭患者190例随机分为对照组(常规药物)和治疗组96例(常规药物治疗＋贝那普利＋美托洛尔缓释片)。两组均连续治疗6个月。治疗前、后行血清和肽素、NT－proBNP浓度检测；并检测慢性心力衰竭患者治疗前、后左心室射血分数(LVEF)、左心室收缩末期内径(LVESD)及左心室舒张末期内径(LVEDD)的变化；对比两组各指标变化的差异。结果：治疗6个月，治疗组与对照组和肽素、NT－proBNP、LVEF、LVESD、LVEDD各指标比较均有统计学意义。结论：贝那普利联合美托洛尔缓释片可降低慢性心力衰竭患者血清和肽素、NT－proBNP的浓度，抑制神经内分泌因子激活，抑制心室重构，改善心功能。
目的：：觀察貝那普利聯閤美託洛爾緩釋片對慢性心力衰竭患者血清和肽素及 N耑腦鈉肽前體(NT－proBNP)的影響，探討貝那普利聯閤美託洛爾緩釋片抑製心室重構的作用機製。方法：慢性心力衰竭患者190例隨機分為對照組(常規藥物)和治療組96例(常規藥物治療＋貝那普利＋美託洛爾緩釋片)。兩組均連續治療6箇月。治療前、後行血清和肽素、NT－proBNP濃度檢測；併檢測慢性心力衰竭患者治療前、後左心室射血分數(LVEF)、左心室收縮末期內徑(LVESD)及左心室舒張末期內徑(LVEDD)的變化；對比兩組各指標變化的差異。結果：治療6箇月，治療組與對照組和肽素、NT－proBNP、LVEF、LVESD、LVEDD各指標比較均有統計學意義。結論：貝那普利聯閤美託洛爾緩釋片可降低慢性心力衰竭患者血清和肽素、NT－proBNP的濃度，抑製神經內分泌因子激活，抑製心室重構，改善心功能。
목적：：관찰패나보리연합미탁락이완석편대만성심력쇠갈환자혈청화태소급 N단뇌납태전체(NT－proBNP)적영향，탐토패나보리연합미탁락이완석편억제심실중구적작용궤제。방법：만성심력쇠갈환자190례수궤분위대조조(상규약물)화치료조96례(상규약물치료＋패나보리＋미탁락이완석편)。량조균련속치료6개월。치료전、후행혈청화태소、NT－proBNP농도검측；병검측만성심력쇠갈환자치료전、후좌심실사혈분수(LVEF)、좌심실수축말기내경(LVESD)급좌심실서장말기내경(LVEDD)적변화；대비량조각지표변화적차이。결과：치료6개월，치료조여대조조화태소、NT－proBNP、LVEF、LVESD、LVEDD각지표비교균유통계학의의。결론：패나보리연합미탁락이완석편가강저만성심력쇠갈환자혈청화태소、NT－proBNP적농도，억제신경내분비인자격활，억제심실중구，개선심공능。
Objective:To investigate the ef ects of benazepril combined with metoprolol succinate sustained-release tablets on plasma copeptin and N terminal brain natriuretic(NT-proBNP)in the pa-tients with chronic heart failure(CHF)in order to explore the mechanism of benazepril combined with metoprolol succinate sustained-release tablets on ventricular remodeling.Methods:190 patients with CHF were randomized into control group(n=)and therapy(n=).Patients in control group were received regular treatment including medicine of treating cardiotonic diuretic and vasodilator for 6months, while in therapy group were give benazepril combined with metoprolol succinate sustained-release tabletsbeside regular treatment.The levels of copeptin NT-proBNP were measured before and after treat-ment.The left ventricular ejection fractiong(LVEF),left ventricular end systolic diameter(LVESD)andleft ventricular end diastole diameter(LVEDD)were recorded and compared before and after treat-ment.Result:After treatment the levels of copeptin,NT-proBNP,LVEF,LVESD and LVEDD in treatment were lower than that of control group,and there was significant dif erence between groups.Con-clusion:Benazepril combined with metoprolol succinate sustained-release tablets treaments could decrease the level of plasma copeptin and NT-proBNP in CHF patients,inhibit neuroendocrine and the ventricular remodeling,and then improve the heart function.
